MCID: PRT034
MIFTS: 20

Peritoneal Serous Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Peritoneal Serous Adenocarcinoma

MalaCards integrated aliases for Peritoneal Serous Adenocarcinoma:

Name: Peritoneal Serous Adenocarcinoma 12 15
Primary Peritoneal Serous Adenocarcinoma 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4901
NCIt 50 C40023
UMLS 73 C1514429

Summaries for Peritoneal Serous Adenocarcinoma

MalaCards based summary : Peritoneal Serous Adenocarcinoma, also known as primary peritoneal serous adenocarcinoma, is related to primary peritoneal carcinoma and lymphocytic colitis. An important gene associated with Peritoneal Serous Adenocarcinoma is SFTPC (Surfactant Protein C). The drugs Paclitaxel and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and ovary, and related phenotypes are Increased viability and cardiovascular system

Related Diseases for Peritoneal Serous Adenocarcinoma

Diseases related to Peritoneal Serous Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 11.4
2 lymphocytic colitis 10.1 CHGA PTGER4
3 malignant epithelial mesothelioma 10.1 PTGER4 WT1
4 benign mesothelioma 10.1 PTGER4 WT1
5 endosalpingiosis 10.1 PTGER4 WT1
6 diffuse pulmonary fibrosis 10.1 CHGA SFTPC
7 nodular hidradenoma 10.1 PIP PTGER4
8 peritoneum cancer 10.1 PTGER4 WT1
9 acute thyroiditis 10.1 CHGA PIP
10 ureter small cell carcinoma 10.1 CHGA SYP
11 small cell carcinoma 10.1 CHGA SYP
12 esophageal neuroendocrine tumor 10.1 CHGA SYP
13 neuroendocrine tumor 10.1 CHGA SYP
14 urinary bladder small cell neuroendocrine carcinoma 10.1 CHGA SYP
15 ovarian large-cell neuroendocrine carcinoma 10.1 CHGA SYP
16 auditory system cancer 10.1 CHGA SYP
17 adenoma of the pancreas 10.1 CHGA SYP
18 acinar cell cystadenocarcinoma 10.1 CHGA SYP
19 cellular ependymoma 10.1 CHGA SYP
20 gallbladder small cell carcinoma 10.1 CHGA SYP
21 primary hepatic neuroendocrine carcinoma 10.1 CHGA SYP
22 small cell carcinoma of the bladder 10.1 CHGA SYP
23 gastrointestinal neuroendocrine tumor 10.1 CHGA SYP
24 pulmonary large cell neuroendocrine carcinoma 10.1 CHGA SYP
25 large cell neuroendocrine carcinoma 10.1 CHGA SYP
26 atypical follicular adenoma 10.1 CHGA SYP
27 chordoid meningioma 10.1 CHGA SYP
28 olfactory groove meningioma 10.1 CHGA SYP
29 pancreatic serous cystadenoma 10.1 CHGA SYP
30 cystadenoma 10.1 CHGA SYP
31 conventional angiosarcoma 10.1 CHGA SYP
32 olfactory nerve neoplasm 10.1 CHGA SYP
33 hemangioma 10.1 CHGA SYP
34 autonomic nervous system benign neoplasm 10.1 CHGA SYP
35 nodular ganglioneuroblastoma 10.1 CHGA SYP
36 pulmonary sclerosing hemangioma 10.1 CHGA SYP
37 sclerosing hemangioma 10.1 CHGA SYP
38 pineocytoma 10.1 CHGA SYP
39 gastric small cell carcinoma 10.1 CHGA SYP
40 pancreatoblastoma 10.1 CHGA SYP
41 breast neuroendocrine neoplasm 10.1 PIP SYP
42 subependymoma 10.1 CHGA SYP
43 carcinoid tumors, intestinal 10.1 CHGA SYP
44 respiratory system benign neoplasm 10.1 CHGA SYP
45 anterior cranial fossa meningioma 10.1 CHGA SYP
46 gastric squamous cell carcinoma 10.0 CHGA SYP
47 pulmonary blastoma 10.0 CHGA SYP
48 pleomorphic xanthoastrocytoma 10.0 CHGA SYP
49 tanycytic ependymoma 10.0 CHGA SYP
50 ovarian small cell carcinoma 10.0 SYP WT1

Graphical network of the top 20 diseases related to Peritoneal Serous Adenocarcinoma:



Diseases related to Peritoneal Serous Adenocarcinoma

Symptoms & Phenotypes for Peritoneal Serous Adenocarcinoma

GenomeRNAi Phenotypes related to Peritoneal Serous Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability GR00386-A-1 9.1 CHGA CLDN4 PIP PTGER4 SYP WT1

MGI Mouse Phenotypes related to Peritoneal Serous Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.1 CHGA CLDN4 PIP PTGER4 SFTPC WT1

Drugs & Therapeutics for Peritoneal Serous Adenocarcinoma

Drugs for Peritoneal Serous Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
3
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
4
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
5
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 3 123948-87-8, 119413-54-6 60700
6
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
7
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
8
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
9
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
10
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
13
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
14
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
15
Maleic acid Experimental Phase 2, Phase 3 110-16-7 444266
16
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
17 Immunoglobulin G Phase 3,Phase 2,Phase 1
18 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
19 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
20 Antibodies Phase 3,Phase 2,Phase 1
21 Immunoglobulins Phase 3,Phase 2,Phase 1
22 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 3,Phase 2,Phase 1
26 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
27 Mitogens Phase 3,Phase 2,Phase 1
28 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
29 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3
30 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
31 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
32 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
33 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
34 topoisomerase I inhibitors Phase 2, Phase 3,Phase 3
35 Carotenoids Phase 3
36 Micronutrients Phase 3,Not Applicable
37 Trace Elements Phase 3,Not Applicable
38 Antimetabolites, Antineoplastic Phase 3,Phase 2
39 Antiviral Agents Phase 3,Phase 2
40 Antimetabolites Phase 3,Phase 2
41 Anti-Infective Agents Phase 3,Phase 2
42 Immunosuppressive Agents Phase 3,Phase 2
43 Bone Density Conservation Agents Phase 2, Phase 3
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
45 Estrogen Antagonists Phase 2, Phase 3
46 Citrate Phase 2, Phase 3
47 Anticoagulants Phase 2, Phase 3
48 Calcium, Dietary Phase 2, Phase 3
49 Steroid Synthesis Inhibitors Phase 2, Phase 3
50 Estrogens Phase 2, Phase 3

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
3 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
4 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
5 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
6 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
7 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
8 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
9 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02923739 Phase 2 Paclitaxel
10 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
11 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
12 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
13 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
14 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
15 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
16 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Not yet recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
17 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
18 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
19 Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn NCT02627430 Phase 1 Hsp90 Inhibitor AT13387;Talazoparib
20 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
21 Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02316834 Early Phase 1 BMN 673
22 Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy Active, not recruiting NCT02111941 Not Applicable
23 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Peritoneal Serous Adenocarcinoma

Genetic Tests for Peritoneal Serous Adenocarcinoma

Anatomical Context for Peritoneal Serous Adenocarcinoma

MalaCards organs/tissues related to Peritoneal Serous Adenocarcinoma:

41
Lung, Kidney, Ovary, Pancreas, Cervix, Thyroid

Publications for Peritoneal Serous Adenocarcinoma

Variations for Peritoneal Serous Adenocarcinoma

Expression for Peritoneal Serous Adenocarcinoma

Search GEO for disease gene expression data for Peritoneal Serous Adenocarcinoma.

Pathways for Peritoneal Serous Adenocarcinoma

GO Terms for Peritoneal Serous Adenocarcinoma

Sources for Peritoneal Serous Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....